Meaningful Use Criteria

The Hitech Act provided for incentives to eligible professionals (EP) and hospitals that have adopted Certified EHR Technology and can demonstrate that they are meaningful users of the technology.

HHS has published the proposed rule governing the criteria for meaningful use. The criteria for meaningful use will be finalized in 2010, following a 60 day comment period.

Extracts of key elements of the proposed rule follow.

Meaningful Use Criteria

In Stage 1 beginning in 2011, meaningful use criteria focuses on electronically capturing health information in a coded format; using that information to track key clinical conditions and communicating that information for care coordination purposes (whether that information is structured or unstructured), implementing clinical decision support tools to facilitate disease and medication management and reporting clinical quality measures and public health information. The rule specifies criteria for Stage 1 only and will be the criteria used for all payment years until updated by future rulemaking. It is intended as new criteria are established in 2013 and 2015, that the Stage 1 criteria is applied to the first payment year.

Stage 2, beginning in 2013, encourages the use of health IT for continuous quality improvement at the point of care and the exchange of information in the most structured format possible, such as the electronic transmission of orders entered using computerized provider order entry (CPOE) and the electronic transmission of diagnostic test results (such as blood tests, microbiology, urinalysis, pulmonary function tests and other data needed to diagnose and treat disease).

Stage 3, beginning in 2015 focuses on promoting improvements in quality, safety and efficiency, focusing on decision support for national high priority conditions, patient access to self management tools, access to comprehensive patient data and improving population health.


Separately issued rules for HIPAA transactions and code sets and e-Prescribing are incorporated into the meaningful use criteria:

• The adoption of the new HIPAA transactions (5010) and ICD-10 code sets are required as part of the Stage 2 and 3 criteria, following the originally published dates leading to ICD-10 implementation starting October 1, 2013.
  

• The use of NCPDP SCRIPT Version 8.1 or 10.6 for e-Prescribing is required.

For the first year only, the EHR Reporting period means any continuous 90-day period during that calendar year in which the EP or eligible hospital demonstrates meaningful use of certified EHR technology. Subsequent years require reporting for the entire calendar year. While this suggests that an EP has until October 1, 2011 to begin meaningful use and still receive an incentive for payment year 2011, such a delay by the EP puts at risk the incentive if the provider fails to meet the related performance criteria (for example CPOE used for 80 percent of all EP orders and 10% of all hospital orders) in the final 90 days of 2011.

Under HITECH, an EP or eligible hospital is considered a meaningful EHR user if they (1) demonstrate use of certified EHR technology in a meaningful manner, (2) demonstrate that the certified EHR technology is connected in a manner that provides for the electronic exchange of health information to improve the quality of health care such as promoting care coordination and (3) using its certified EHR technology submits information on specified clinical quality measures and other measures.

For Medicaid incentives in the initial payment year, the EP or eligible hospital may demonstrate that they have engaged in efforts to adopt, implement or upgrade certified EHR technology. For Medicaid incentives in subsequent payment years, they must demonstrate that they are meaningful users of the certified EHR technology, in a similar manner to the criteria under Medicare, but with states having the option to add additional objectives or to modify how the existing objectives are measured.

Each meaningful use objective must be satisfied by an individual EP as determined by unique National Provider Identifiers (NPIs) and an individual hospital as determined by unique CMS certification numbers (CCN).

Objectives

1. Health outcomes policy priority: Improve quality, safety, efficiency and reduce health disparities

Care goals:

• Provide access to comprehensive patient health data for patient's healthcare team.
• Use evidence-based order sets and computerized provider order entry (CPOE).
• Apply clinical decision support at the point of care.
• Generate lists of patients who need care and use them to reach out to those patients.
• Report information for quality improvement and public reporting.

EP objectives and measures:

• Use CPOE. CPOE is used for at least 80 percent of all orders
• Implement drug-drug, drug-allergy, drug-formulary checks. The EP has enabled this functionality.
  
• Maintain an up-to-date problem list of current and active diagnoses based on ICD-9-CM or SNOMED CT®. At least 80 percent of all unique patients seen by the EP have at least one entry or an indication of none recorded as structured data.
  
• Generate and transmit permissible prescriptions electronically (eRx). At least 75 percent of all permissible prescriptions written by the EP are transmitted electronically using certified EHR technology.
  
• Maintain active medication list. At least 80 percent of all unique patients seen by the EP have at least one entry (or an indication of “none” if the patient is not currently prescribed any medication) recorded as structured data.
• Maintain active medication allergy list. At least 80 percent of all unique patients seen by
  the EP have at least one entry (or an indication of “none” if the patient has no medication allergies) recorded as structured data.
  
• Record the following demographics: preferred language, insurance type, gender, race and ethnicity, and date of birth. At least 80 percent of all unique patients seen by the EP have demographics recorded as structured data
  
• Record and chart changes in the following vital signs: height, weight and blood pressure and calculate and display body mass index (BMI) for ages 2 and over; plot and display growth charts for children 2 - 20 years, including BMI. For at least 80 percent of all unique patients age 2 and over seen by the EP, record blood pressure and BMI; additionally, plot growth chart for children age 2 to 20.
• Record smoking status for patients 13 years old or older. At least 80 percent of all unique patients 13 years old or older seen by the EP have “smoking status” recorded.
  
• Incorporate clinical lab-test results into EHR as structured data. At least 50 percent of all clinical lab tests results ordered by the EP during the EHR reporting period whose results are in either in a positive/negative or numerical format are incorporated in certified EHR technology as structured data.
  
• Generate lists of patients by specific conditions to use for quality improvement, reduction of disparities, research, and outreach. Generate at least one report listing patients of the EP with a specific condition.
  
• Report ambulatory quality measures to CMS (or, for EPs seeking the Medicaid incentive payment, the States). For 2011, an EP would provide the aggregate numerator and denominator through attestation. For 2012, an EP would electronically submit the quality measures.
  
• Send reminders to patients per patient preference for preventive/follow-up care. Patient preference refers to the patient's choice of delivery method between internet based delivery or delivery not requiring internet access. Reminder sent to at least 50 percent of all unique patients seen by the EP or admitted to the eligible hospital that are 50 and over. (Editor's note: Not sure why "admitted to the eligible hospital" is included here as this is an EP-only objective.)
  
• Implement five clinical decision support rules relevant to specialty or high clinical priority, including for diagnostic test ordering, along with the ability to track compliance with those rules. Clinical decision support is defined as health information technology functionality that builds upon the foundation of an EHR to provide persons involved in care processes with general and person-specific information, intelligently filtered and organized, at appropriate times, to enhance health and health care. An EP should implement five clinical decision support rules relevant to the clinical quality metrics before the end of the EHR reporting period and attest to that implementation.
  
• Check insurance eligibility electronically from public and private payers. Insurance eligibility checked electronically for at least 80 percent of all unique patients seen by the EP
  
• Submit claims electronically to public and private payers. At least 80 percent of all claims filed electronically by the EP.
  

Eligible hospital objectives and measures:

• Use CPOE for orders (any type) directly entered by the authorizing provider
  (for example, MD, DO, RN, PA, NP). CPOE is used for at least 10 percent of all orders.
  
• Implement drug-drug, drug-allergy, drug-formulary checks. The eligible hospital has enabled this functionality.
  
• Maintain an up-to-date problem list of current and active diagnoses based on
  ICD-9-CM or SNOMED CT®. At least 80 percent of all unique patients admitted to the eligible hospital have at least one entry or an indication of none recorded as structured data.
  
• Maintain active medication list. At least 80 percent of all unique patients admitted by the eligible hospital have at least one entry (or an indication of “none” if the patient is not currently prescribed any medication) recorded as structured data.
• Maintain active medication allergy list. At least 80 percent of all unique patients admitted to the eligible hospital have at least one entry (or an indication of “none” if the patient has no medication allergies) recorded as structured data.
  
• Record the following demographics: preferred language, insurance type,
  gender, race and ethnicity, date of birth, and date and cause of death in the event of
  mortality. At least 80 percent of all unique patients admitted to the eligible hospital have demographics recorded as structured data.
• Record the following vital signs: height, weight and blood pressure and
  calculate and display body mass index (BMI) for patients 2 and over; plot and display
  growth charts for children 2 - 20 years, including BMI. For at least 80 percent of all unique patients age 2 and over admitted to the eligible hospital, record blood pressure and BMI; additionally, plot growth chart for children age 2 to 20.
  
• Record smoking status for patients 13 years old or older. At least 80 percent of all unique patients 13 years old or older admitted to the eligible hospital have “smoking status” recorded.
• Incorporate clinical lab-test results into EHR as structured data. At least 50 percent of all clinical lab tests results ordered by an authorized provider of the eligible hospital during the EHR reporting period whose results are in either in a positive/negative or numerical format are incorporated in certified EHR technology as structured data.
• Generate lists of patients by specific conditions to use for quality improvement, reduction of disparities, and outreach. Generate at least one report listing patients eligible hospital with a specific condition.
  
• Report ambulatory quality measures to CMS (or, for eligible hospitals seeking
  the Medicaid incentive payment, the States). For 2011, an eligible hospital would provide the aggregate numerator and denominator through attestation. For 2012, an eligible hospital would electronically submit the measures.
  
• Implement five clinical decision support rules relevant to specialty or high
  clinical priority, including for diagnostic test ordering, along with the ability to track
  compliance with those rules. An eligible hospital should implement five clinical decision support rules relevant to the clinical quality metrics before the end of the EHR reporting period and attest to that implementation.
• Check insurance eligibility electronically from public and private payers. Insurance eligibility checked electronically for at least 80 percent of all unique patients admitted to an eligible hospital
  
• Submit claims electronically to public and private payers. At least 80 percent of all claims filed electronically by the eligible hospital.
  

2. Health outcomes policy priority: Engage patients and families in their healthcare.

Care goal:

• Provide patients and families with timely access to data, knowledge, and tools to make informed decisions and to manage their health.

EP objectives:

• Provide patients with an electronic copy of their health information (including diagnostics test results, problem list, medication lists, allergies) upon request. Electronic copies may be provided through a number of secure electronic methods (for example, personal health record (PHR), patient portal, CD, USB drive). At least 80 percent of all patients who request an electronic copy of their health information are provided it within 48 hours.
  
• Provide patients with timely electronic access to their health information (including lab results, problem list, medication lists, allergies) within 96 hours of the information being available to the EP either through the receipt of final lab results or a patient interaction that updates the EP's knowledge of the patient's health. At least 10 percent of all unique patients seen by the EP are provided timely electronic access to their health information
  
• Provide clinical summaries for patients for each office visit. Clinical summaries provided to patients for at least 80 percent of all office visits.
  

Eligible hospital objectives:

• Provide patients with an electronic copy of their health information (including diagnostic test results, problem list, medication lists, allergies, discharge summary, procedures), upon request. At least 80 percent of all patients who are discharged from an eligible hospital and who request an electronic copy of their discharge instructions and procedures are provided it.
  
• Provide patients with an electronic copy of their discharge instructions and procedures at time of discharge, upon request.
  

3. Health outcomes policy priority: Improve care coordination.

Care goal:

• Exchange meaningful clinical information among professional health care team

EP and eligible hospital objectives:

• Capability to exchange key clinical information (for example, problem list, medication list, allergies, and diagnostic test results), among providers of care and patient authorized entities electronically. Performed at least one test of certified EHR technology's capacity to electronically exchange key clinical information. To be considered an “exchange” in this section alone the clinical information must be sent between different clinical entities with distinct certified EHR technology and not between organizations that share a certified EHR.
  
• Perform medication reconciliation at relevant encounters and each transition of care. Perform medication reconciliation for at least 80 percent of relevant encounters and transitions of care.
  
• Provide summary care record for each transition of care or referral. Provide summary of care record for at least 80 percent of transitions of care and referrals.
  

4. Health outcomes policy priority: Improving population and public health

Care goal:

• The patient's health care team communicates with public health agencies.

EP objectives:

• Capability to submit electronic data to immunization registries and actual submission where possible and accepted. Performed at least one test of certified EHR technology's capacity to submit electronic data to immunization registries.
  
• Capability to provide electronic syndromic surveillance data to public health agencies and actual transmission according to applicable law and practice. Performed at least one test of certified EHR technology's capacity to provide electronic syndromic surveillance data to public health agencies (unless none of the public health agencies to which an EP or eligible hospital submits such information have the capacity to receive the information electronically). More stringent requirements may be established for EPs and hospitals under the Medicaid program in States where this capability exists. This is just one example of a possible State proposed modification to meaningful use in the Medicaid EHR incentive program. States may propose any modification or addition to CMS in accordance with the discussion in II.A.2.c. of this proposed rule.
  

Eligible hospital objectives:

• Capability to submit electronic data to immunization registries and actual submission where required and accepted.
• Capability to provide electronic submission of reportable (as required by state or local law) lab results to public health agencies and actual submission where it can be received. Performed at least one test of certified EHR technology capacity to provide electronic submission of reportable lab results to public health agencies (unless none of the public health agencies to which eligible hospital submits such information have the capacity to receive the information electronically).
  
• Capability to provide electronic syndromic surveillance data to public health agencies and actual transmission according to applicable law and practice. Performed at least one test of certified EHR technology's capacity to provide electronic syndromic surveillance data to public health agencies (unless none of the public health agencies to which an EP or eligible hospital submits such information have the capacity to receive the information electronically).

5. Health outcomes policy priority: Ensure adequate privacy and security protections for personal health information.

Care goals:

• Ensure privacy and security protections for confidential information through operating policies, procedures, and technologies and compliance with applicable law.
• Provide transparency of data sharing to patient.

EP and eligible hospitals objective:

• Protect electronic health information created or maintained by the certified EHR technology through the implementation of appropriate technical capabilities. The intent is to ensure that meaningful use of the certified EHR technology supports compliance with the HIPAA Privacy and Security Rules and compliance with fair sharing data practices outlined in the Nationwide Privacy and Security Framework. However, meaningful use of certified EHR technology is not the appropriate regulatory tool to ensure such compliance with the HIPAA Privacy and Security Rules. EPs and eligible hospitals conduct or review a security risk analysis of certified EHR technology and implement security updates as necessary at least once prior to the end of the EHR reporting period and attest to that conduct or review. The testing could occur prior to the beginning of the EHR reporting period.
  

Editor's note on challenges:

• Many of the measures listed above require denominators which track manual activity (e.g., the number of orders that were written outside of the EHR).
• Also, providers working in multiple locations and with multiple EHR's need to have this information combined for CMS reporting.
  
• Not clear how this works for providers working across multiple organizations with separate EHRs.

Quality measures
Starting in 2011, to be a meaningful user, EPs and eligible hospitals will be required to use certified EHR technology to capture the data elements and calculate the results for the applicable clinical quality measures. EPs and eligible hospitals must demonstrate that they have satisfied this requirement during the EHR reporting period for 2011 through attestation.

Medicare EPs and eligible hospital attest to the accuracy and completeness of the numerators and denominators for each of the applicable measure. EPs and eligible hospitals must demonstrate their use of certified EHR technology to capture the data elements and calculate the results for the applicable clinical quality measures by reporting the results to CMS for all applicable patients.

For the Medicaid incentive program, States may accept provider attestations in the same manner to demonstrate meaningful use in 2011. However, we expect that Medicaid providers will qualify for the incentive payment by adopting, implementing, or upgrading to certified EHR technology, and therefore; will not need to attest to meaningful use of EHRs in 2011, for their first payment year.

Final detailed specification documents for all 2011 Medicare incentive-related clinical quality measures will be posted on the CMS website April 1, 2010

For 2011 and 2012 EHR reporting periods, most quality measures are already documented through PQRI or NQF. The following quality measures are proposed with each measure associated with core/specialty measure group(s):

• Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus - Percentage of patients aged 18 through 75 years with diabetes mellitus who had most recent hemoglobin A1c greater than 9.0%
• Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus - Percentage of patients aged 18 through 75 years with diabetes mellitus who had most recent LDL-C level in
• control (less than 100 mg/dl)
• Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus - Percentage of patients aged 18 through 75 years with diabetes mellitus who had most recent blood pressure in control (less than 140/80 mmHg)
• Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) - Percentage of patients aged 18 years and older with a diagnosis of heart failure and LVSD who were prescribed ACE inhibitor or ARB therapy
• Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) - Percentage of patients aged 18 years and older with a diagnosis of CAD and prior MI who were prescribed betablocker therapy
• Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old - Percentage of patients aged 50 years and older who received an influenza immunization during the flu season (September through February)
• Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older - Percentage of patients aged 65 years and older who have ever received a pneumococcal vaccine
• Preventive Care and Screening: Screening Mammography - Percentage of women aged 40 through 69 years who had a mammogram to screen for breast cancer within 24 months
• Preventive Care and Screening: Colorectal Cancer Screening - Percentage of patients aged 50 through 80 years who received the appropriate colorectal cancer screening
• Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD - Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed oral antiplatelet therapy
• Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) - Percentage of patients aged 18 years and older with a diagnosis of heart failure who also have LVSD and who were prescribed beta-blocker therapy
• Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD - Percentage of patients aged 18 years and older diagnosed with new episode of MDD and documented as treated with antidepressant medication during the entire 84-day (12-week) acute treatment phase
• Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports - Percentage of final reports for CT or MRI studies of the brain performed within 24 hours of arrival to the hospital for patients aged 18 years and older with either a diagnosis of ischemic stroke or transient ischemic attack (TIA) or intracranial hemorrhage or at least one documented symptom consistent with ischemic stroke or TIA or intracranial hemorrhage that includes documentation of the presence or absence or each of the following: hemorrhage and mass lesion and acute infarction.
• Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation - Percentage of patients aged 18 years and older with a diagnosis of POAG who have an optic nerve head evaluation during one or more office visits within 12 months
• Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy - Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months
• Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care - Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the on-going care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months
• Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician - Percentage of surgical patients aged 18 years and older undergoing procedures with the indications for prophylactic parenteral antibiotics, who have an order for prophylactic antibiotic to be given within one hour (if fluoroquinolone or vancomycin, two hours), prior to the surgical incision (or start of procedure when no incision is required)
• Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin - Percentage of surgical patients aged 18 years and older undergoing procedures with the indications for a first OR second generation cephalosporin prophylactic antibiotic, who had an order for cefazolin OR cefuroxime for antimicrobial prophylaxis
• Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures) - Percentage of non-cardiac surgical patients aged 18 years and older undergoing procedures with the indications for prophylactic antibiotics AND who received a prophylactic antibiotic, who have an order for discontinuation of prophylactic antibiotics within 24 hours of surgical end time
• Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) - Percentage of patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients, who had an order for Low Molecular Weight Heparin (LMWH), Low-Dose Unfractionated Heparin (LDUH), adjusteddose warfarin, fondaparinux or mechanical prophylaxis to be given within 24 hours prior to incision time or within 24 hours after surgery end time
• Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge - Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke or transient ischemic attack (TIA) with documented permanent, persistent, or paroxysmal atrial fibrillation who were prescribed an anticoagulant at discharge
• Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy - Percentage of patients aged 18 years and older with a diagnosis of COPD and who have an FEV1/FVC less than 70% and have symptoms who were prescribed an inhaled bronchodilator
• Asthma: Pharmacologic Therapy - Percentage of patients aged 5 through 40 years with a diagnosis of mild, moderate, or severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment
• Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use - Percentage of children aged 3 months through 18 years with a diagnosis of URI who were not prescribed or dispensed an antibiotic prescription on or within 3 days of the initial date of service
• Appropriate Testing for Children with Pharyngitis - Percentage of children aged 2 through 18 years with a diagnosis of pharyngitis, who were prescribed an antibiotic and who received a group A streptococcus (strep) test for the episode
• Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer - Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period
• Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients - Percentage of patients aged 18 years and older with Stage IIIA through IIIC colon cancer who are referred for adjuvant, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period
• End Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis in ESRD Patients - Percentage of calendar months during the 12-month reporting period in which patients aged 18 years and older with a diagnosis of ESRD receiving hemodialysis have a Kt/V ≥ 1.2 OR patients who have a Kt/V <>
• End Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal Dialysis - Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving peritoneal dialysis who have a Kt/V ≥ 1.7 OR patients who have a Kt/V <>
• Hepatitis C: Antiviral Treatment Prescribed - Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who were prescribed peginterferon and ribavirin therapy within the 12-month reporting period
• Hepatitis C: Counseling Regarding Risk of Alcohol Consumption - Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who were counseled about the risks of alcohol use at least once within the 12-month reporting period
• Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients - Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer
• Major Depressive Disorder (MDD): Diagnostic Evaluation - Percentage of patients aged 18 years and older with a new diagnosis or recurrent episode of MDD who met the DSM-IV criteria during the visit in which the new diagnosis or recurrent episode was identified during the measurement period
• Major Depressive Disorder (MDD): Suicide Risk Assessment - Percentage of patients aged 18 years and older with a new diagnosis or recurrent episode of MDD who had a suicide risk assessment completed at each visit during the measurement period
• Preventive Care and Screening: Inquiry Regarding Tobacco Use - Percentage of patients aged 18 years or older who were queried about tobacco use one or more times within 24 months
• Preventive Care and Screening: Advising Smokers to Quit - Percentage of patients aged 18 years and older and are smokers who received advice to quit smoking
• Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient - Percentage of patients aged 18 through 75 years with a diagnosis of diabetes mellitus who had a dilated eye exam
• Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left
• Ventricular Systolic Dysfunction (LVSD) - Percentage of patients aged 18 years and older with a diagnosis of CAD who also have diabetes mellitus and/or LVSD (LVEF <>
• Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients - Percentage of patients aged 18 through 75 years with diabetes mellitus who received urine protein screening or medical attention for nephropathy during at least one office visit within 12 months
• Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile) - Percentage of patients aged 18 years and older with a diagnosis of advanced CKD (stage 4 or 5, not receiving Renal Replacement Therapy [RRT]), who had the following laboratory testing ordered within 12 months: serum levels of calcium, phosphorus and intact PTH, and lipid profile
• Chronic Kidney Disease (CKD): Blood Pressure Management - Percentage of patient visits for patients aged 18 years and older with a diagnosis of advanced CKD (stage 4 or 5, not receiving Renal Replacement Therapy [RRT]), with a blood pressure <>
• Chronic Kidney Disease (CKD): Plan of Care – Elevated Hemoglobin for Patients Receiving Erythropoiesis-Stimulating Agents (ESA) - Percentage of calendar months during the 12-month reporting period in which patients aged 18 years and older with a diagnosis of advanced CKD (stage 4 or 5, not receiving Renal Replacement Therapy [RRT]), receiving ESA therapy, have a hemoglobin <>
• Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear - Percentage of patients aged 18 years and older with a diagnosis of diabetes mellitus who were evaluated for proper footwear and sizing
• Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up - Percentage of patients aged 18 years and older with a calculated BMI in the past six months or during the current visit documented in the medical record AND if the most recent BMI is outside parameters, a follow-up plan is documented. Parameters: Age 65 and older BMI ≥30 or <22>
• Radiology: Exposure Time Reported for Procedures Using Fluoroscopy - Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time
• Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening - Percentage of final reports for screening mammograms that are classified as “probably benign”
• Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy - Percentage of final reports for all patients, regardless of age, undergoing bone scintigraphy that include physician documentation of correlation with existing relevant imaging studies (e.g., x-ray, MRI, CT, etc.) that were performed
• Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula - Percentage of patients aged 18 years and older with the diagnosis of advanced CKD (stage 4 or 5, not receiving Renal Replacement Therapy [RRT]), who were referred for AV fistula at least once during the 12-month reporting period
• Diabetes Mellitus: Foot Exam - The percentage of patients aged 18 through 75 years with diabetes who had a foot examination
• Hepatitis C: Hepatitis A Vaccination in Patients with HCV - Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who received at least one injection of hepatitis A vaccine, or who have documented immunity to hepatitis A
• Hepatitis C: Hepatitis B Vaccination in Patients with HCV - Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who received at least one injection of hepatitis B vaccine, or who have documented immunity to hepatitis B
• Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use - Percentage of patients aged 18 years and older receiving a surveillance colonoscopy and a history of colonic polyp(s) in a previous colonoscopy, who had a follow-up interval of 3 or more years since their last colonoscopy documented in the colonoscopy report
• Stenosis Measurement in Carotid Imaging Reports - Percentage of final reports for carotid imaging studies (neck MR angiography [MRA], neck CT angiography [CTA], neck duplex ultrasound, carotid angiogram) performed for patients aged 18 years and older with the diagnosis of ischemic stroke or transient ischemic attack (TIA) that include direct or indirect reference to measurements of distal internal carotid diameter as the denominator for stenosis measurement
• Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol - Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed a lipid-lowering therapy (based on current ACC/AHA guidelines)
• Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation - Percentage of all patients aged 18 and older with a diagnosis of heart failure and paroxysmal or chronic atrial fibrillation who were prescribed warfarin therapy
• Ischemic Vascular Disease (IVD): Blood Pressure Management Control - Percentage of patients aged 18 years and older with Ischemic Vascular Disease (IVD) who had most recent blood pressure in control (less than 140/90 mmHg)
• Ischemic Vascular Disease (IVD): Complete Lipid Profile - Percentage of patients aged 18 years and older with Ischemic Vascular Disease (IVD) who received at least one lipid profile within 12 months
• Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL–C) Control - Percentage of patients aged 18 years and older with Ischemic Vascular Disease (IVD) who had most recent LDL-C level in control (less than 100 mg/dl)
• Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic - Percentage of patients aged 18 years and older with Ischemic Vascular Disease (IVD) with documented use of aspirin or other antithrombotic
• Asthma assessment - Percentage of patients who were evaluated during at least one office visit for the frequency (numeric) of daytime and nocturnal asthma symptoms
• Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement - Percentage of adults aged 18 and over diagnosed with AOD abuse or dependence and receiving a related service who initiate treatment Assessment of the degree to which members engage in treatment with two additional AOD treatments within 30 days after initiating treatment.
• Prenatal Screening for Human Immunodeficiency Virus (HIV) - Percentage of patients who gave birth during a 12-month period who were screened for HIV infection during the first or second prenatal care visit
• Blood pressure measurement - Percentage of patient visits with blood pressure measurement recorded among all patient visits for patients aged > 18 years with diagnosed hypertension.
• Prenatal Anti-D Immune Globulin - Percentage of D-negative, unsensitized patients who gave birth during a 12-month period who received anti-D immune globulin at 26-30 weeks gestation
• Controlling High Blood Pressure - Percentage of patients with last BP <>
• Drugs to be avoided in the elderly: a. Patients who receive at least one drug to be avoided, b. Patients who receive at least two different drugs to be avoided. - Percentage of patients ages 65 years and older who received at least one drug to be avoided in the elderly in the measurement year. Percentage of patients 65 years of age and older who received at least two different drugs to be avoided in the elderly in the measurement year.
• Body Mass Index (BMI) 2 through 18 years of age - Percentage children, 2 through 18 years of age, whose weight is classified based on BMI percentile for age and gender
• Measure pair - a. Tobacco use prevention for infants, children and adolescents, b. Tobacco use cessation for infants, children and adolescents - Percentage of patients' charts showing either that there is no tobacco use/exposure or (if a user) that the current use was documented at the most recent clinic visit. Percentage of patients with documented tobacco use or exposure at the latest visit who also have documentation that their cessation interest was assessed or that they received advice to quit.
• Cervical Cancer Screening - Percentage of women 18-64 years of age, who received one or more Pap tests during the measurement year or the 2 years prior to the measurement year.
• Chlamydia screening in women - Percentage of eligible women who were identified as sexually active who had at least one test for chlamydia during the measurement year.
• Use of appropriate medications for people with asthma - Percentage of patients who were identified as having persistent asthma during the measurement year and the year prior to the measurement year and who were dispensed a prescription for either an inhaled corticosteroid or acceptable alternative medication during the measurement year.
• Childhood Immunization Status - Percentage of children 2 years of age who had four DtaP/DT, three IPV, one MMR, three H influenza type B, three hepatitis B, one chicken pox vaccine (VZV) and four pneumococcal conjugate vaccines by their second birthday. The measure calculates a rate for each vaccine and two separate combination rates.
• Low back pain: use of imaging studies - Percentage of patients with new low back pain
• who received an imaging study (plain x-ray, MRI, CT scan) conducted on the episode start date or in the 28 days following the episode start date.
• Hemoglobin A1c test for pediatric patients - Percentage of pediatric patients with diabetes with a HBA1c test in a 12-month measurement period.
• New Episode of Depression: (a) Optimal Practitioner Contacts for Medication Management, (b) Effective Acute Phase Treatment,(c)Effective Continuation Phase Treatment - Percentage of patients who were diagnosed with a new episode of depression and treated with antidepressant medication, and who had at least three follow-up contacts with a practitioner during the 84-day (12-week) Acute Treatment. Phase b. Percentage of patients who were diagnosed with a new episode of depression, were treated with antidepressant medication and remained on an antidepressant drug during the entire 84-day Acute Treatment. Phase c. Percentage of patients who were diagnosed with a new episode of depression and treated with antidepressant medication and who remained on an antidepressant drug for at least 180 days.
• Diagnosis of attention deficit hyperactivity disorder (ADHD) in primary care for school age children and adolescents - Percentage of patients newly diagnosed with attention deficit hyperactivity disorder (ADHD) whose medical record contains documentation of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or Diagnostic and Statistical Manual for Primary Care (DSM-PC) criteria being addressed.
• Management of attention deficit hyperactivity disorder (ADHD) in primary care for school age children and adolescents - Percentage of patients diagnosed with attention deficit hyperactivity disorder (ADHD) and on first-line medication whose medical record contains documentation of a follow-up visit twice a year.
• ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication. - a. Initiation Phase: Percentage of children 6 – 12 years of age as of the Index Prescription Episode Start Date with an ambulatory prescription dispensed for and ADHD medication and who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation. Phase b. Continuation and Maintenance (C&M) Phase: Percentage of children 6 – 12 years of age as of the Index Prescription Episode Start Date with an ambulatory prescription dispensed for ADHD medication who remained on the medication for at least 210 days and who in addition to the visit in the Initiation Phase had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ends.
• Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use - Percentage of patients with depression or bipolar disorder with evidence of an initial assessment that includes an appraisal for alcohol or chemical substance use
• Surgical Site Infection Rate - Percentage of surgical site infections occurring within thirty days after the operative procedure if no implant is left in place or with one year if an implant is in place in patients who had an NHSN operative procedure performed during a specified time period and the infection appears to be related to the operative procedure.
• Cesarean Rate for low-risk first birth women (aka NTSV CS rate) - Percentage of low-risk first birth women (aka NTSV CS rate: nulliparous, term, singleton, vertex) with a Cesarean rate that has the most variation among practicioners, hospitals, regions and states. Unlike other cesarean measures, it focuses attention on the proportion of cesarean births that is affected by elective medical practices such as induction and early labor admission. Furthermore, the success (or lack thereof) of management of the first labor directly impacts the remainder of the woman's reproductive life (especially given the current high rate of repeat cesarean births).
• Use of Contrast: Thorax CT - Use of combined studies (with and without contrast)
• Diabetic Foot Care and Patient Education Implemented - Percent of diabetic patients for whom physician ordered monitoring for the presence of skin lesions on the lower extremities and patient education on proper foot care were implemented during their episode of care
• Comprehensive Diabetes Care: HbA1c Control (<8.0%)>
• Hysterectomy rates
• Appropriate antibiotic use for ear infections
• Statin after Myocardial Infarction
• 30 day Readmission Rate
• 30 Readmission Rate following deliveries
• Use of CT scans - Number of repeat CT scans within 60 days

Clinical Quality Measures Reporting Criteria for EPs for the 2011 and 2012 EHR reporting periods requires each EP to submit information on two measure groups: the core
measures and the subset of clinical measures most appropriate given the EPs specialty.

Core measures include 1) preventive care and screening: inquiry regarding tobacco use, 2) blood pressure measurement, and 3) Drugs to be avoided in the elderly.

The second required measure set for each EP is to submit information on at least one of the sets of measures for specialty groups. The specialty groups are Cardiology, Pulmonology, Endocrinology, Oncology, Proceduralist/Surgery, Primary Care Physicians, Pediatrics, Obstetrics and Gynecology, Neurology, Psychiatry, Ophthalmology, Podiatry, Radiology, Gastroenterology, and Nephrology.

The denominator of clinical quality measures and the applicability of a measure is determined by the patient population to whom the measure applies and the services rendered by the particular EP.

Clinical Quality Measures for Electronic Submission by Eligible Hospitals will be required to report summary data to CMS on the set of clinical quality measures including:

• Emergency Department Throughput - a) Median time from emergency department arrival to time of departure from the emergency room for patients admitted to the facility from the emergency department b) Median time from admit decision time to time of departure from the emergency department of emergency department patients admitted to inpatient status, c) Median Time from ED arrival to time of departure from the ED for patients discharged from the ED
• Ischemic stroke – Discharge on anti-thrombotics - Ischemic stroke patients prescribed antithrombotic therapy at hospital discharge
• Ischemic stroke – Anticoagulation for A-fib/flutter - Ischemic stroke patients with atrial fibrillation/flutter who are prescribed anticoagulation therapy at hospital discharge.
• Ischemic stroke – Thrombolytic therapy for patients arriving within 2 hours of symptom onset - Acute ischemic stroke patients who arrive at this hospital within 2 hours of time last known well and for whom IV t-PA was initiated at this hospital within 3 hours of time last known well.
• Ischemic or hemorrhagic stroke – Antithrombotic therapy by day 2 - Ischemic stroke patients administered antithrombotic therapy by the end of hospital day 2.
• Ischemic stroke – Discharge on statins - Ischemic stroke patients with LDL > 100 mg/dL, or LDL not measured, or, who were on a lipid-lowering medication prior to hospital arrival are prescribed statin medication at hospital discharge.
• Ischemic or hemorrhagic stroke – Stroke education - Ischemic or hemorrhagic stroke patients or their caregivers who were given educational materials during the hospital stay addressing all of the following: activation of emergency medical system, need for follow-up after discharge, medications prescribed at discharge, risk factors for stroke, and warning signs and symptoms of stroke.
• Ischemic or hemorrhagic stroke – Rehabilitation assessment - Ischemic or hemorrhagic stroke patients who were assessed for rehabilitation services.
• VTE prophylaxis within 24 hours of arrival - This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission or surgery end date for surgeries that start the day of or the day after hospital admission.
• ICU VTE prophylaxis - This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after the initial admission (or transfer) to the Intensive Care Unit (ICU) or surgery end date for surgeries that start the day of or the day after ICU admission (or transfer).
• Anticoagulation overlap therapy - This measure assesses the number of patients diagnosed with confirmed VTE who received an overlap of parenteral (intravenous [IV] or subcutaneous [subcu]) anticoagulation and warfarin therapy. For patients who received less than five days of overlap therapy, they must be discharged on both medications. Overlap therapy must be administered for at least five days with an international normalized ratio (INR) ≥ 2 prior to discontinuation of the parenteral anticoagulation therapy or the patient must be discharged on both medications.
• Platelet monitoring on unfractionated heparin - This measure assesses the number of patients diagnosed with confirmed VTE who received intravenous (IV) UFH therapy dosages AND had their platelet counts monitored using defined parameters such as a nomogram or protocol.
• VTE discharge instructions - This measure assesses the number of patients diagnosed with confirmed VTE that are discharged to home, to home with home health, home hospice or discharged/transferred to court/law enforcement on warfarin with written discharge instructions that address all four criteria: compliance issues, dietary advice, follow-up monitoring, and information about the potential for adverse drug reactions/interactions.
• Incidence of potentially preventable VTE - This measure assesses the number of patients diagnosed with confirmed VTE during hospitalization (not present on arrival) who did not receive VTE prophylaxis between hospital admission and the day before the VTE diagnostic testing order date.
• Primary PCI Received Within 90 Minutes of Hospital Arrival - Acute myocardial infarction (AMI) patients with ST-segment elevation or LBBB on the ECG closest to arrival time receiving primary PCI during the hospital stay with a time from hospital arrival to PCI of 90 minutes or less
• Blood Cultures Performed in the Emergency Department Prior to Initial Antibiotic Received in Hospital - Pneumonia patients whose initial emergency room blood culture specimen was collected prior to first hospital dose of antibiotics. This measure focuses on the treatment provided to Emergency Department patients prior to admission orders.
• Aspirin Prescribed at Discharge - Acute myocardial infarction (AMI) patients who are prescribed aspirin at hospital discharge
• Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) for Left Ventricular Systolic Dysfunction (LVSD) - Acute myocardial infarction (AMI) patients with left ventricular systolic dysfunction (LVSD) who are prescribed an ACEI or ARB at hospital discharge. For purposes of this measure, LVSD is defined as chart documentation of a left ventricular ejection fraction (LVEF) less than 40% or a narrative description of left ventricular systolic (LVS) function consistent with moderate or severe systolic dysfunction.
• Beta-Blocker Prescribed at Discharge - Acute myocardial infarction (AMI) patients who are prescribed a beta-blocker at hospital discharge
• Hospital Specific 30 day Risk-Standardized Readmission Rate following AMI admission
• Hospital Specific 30 day Rate following AMI admission
• Hospital Specific 30 day Risk-Standardized
• Readmission Rate following Heart Failure admission
• Hospital Specific 30 day Rate following Heart Failure admission
• Hospital Specific 30 day Risk-Standardized Readmission Rate following Pneumonia admission
• Hospital Specific 30 day Rate following Pneumonia admission
• Infection SCIP Inf-2 Prophylactic antibiotics consistent with current recommendations - Surgical patients who received prophylactic antibiotics consistent with current guidelines (specific to each type of surgical procedure).
• Ventilator Bundle - Percentage of intensive care unit patients on mechanical ventilation at time of survey for whom all four elements of the ventilator bundle are documented and in place. The ventilator bundle elements are: •Head of bed (HOB) elevation 30 degrees or greater (unless medically contraindicated); noted on 2 different shifts within a 24 hour period •Daily “sedation interruption” and daily assessment of readiness to extubate; process includes interrupting sedation until patient follow commands and patient is assessed for discontinuation of mechanical ventilation; Parameters of discontinuation include: resolution of reason for intubation; inspired oxygen content roughly 40%; assessment of patients ability to defend airway after extubation due to heavy sedation; minute ventilation less than equal to 15 liters/minute; and respiratory rate/tidal volume less than or equal to 105/min/L(RR/TV<>
• Ventilator-associated pneumonia for ICU and high-risk nursery (HRN) patients - Percentage of ICU and HRN patients who over a certain amount of days have ventilator-associated pneumonia
  
• Urinary catheter-associated urinary tract infection for intensive care unit (ICU) patients - Percentage of intensive care unit patients with urinary catheter-associated urinary tract infections
  
• Central line catheter-associated blood stream infection rate for ICU and high-risk nursery (HRN) patients - Percentage of ICU and high-risk nursery patients, who over a certain amount of days acquired a central line catheter-associated blood stream infections over a specified amount of line-days
  
• All-Cause Readmission Index (risk adjusted) - Overall inpatient 30-day hospital readmission rate.
  
• All-Cause Readmission Index - Overall inpatient 30-day hospital readmission rate.
  
• PICU Pain Assessment on Admission - Percentage of PICU patients receiving: a. Pain assessment on admission b. Periodic pain assessment
  
• Iotrogenic pneumothorax in non-neonates (pediatric up to 17 years of age) - Percent of medical and surgical discharges, age under 18 years, with ICD-9-CM code of iatrogenic pneumothorax in any secondary diagnosis field.
  
• Foreign body left after procedure, age under 18 years - Discharges with foreign body accidentally left in during procedure per 1,000 discharges
  
• Pneumonia Care PNE-5c Antibiotic - Percentage of pneumonia patients 18 years of age and older who receive their first dose of antibiotics within 6 hours after arrival at the hospital
  
• Pneumonia Care PN-6 Antibiotic selection - Percentage of pneumonia patients 18 years of age or older selected for initial receipts of antibiotics for community acquired pneumonia (CAP).
  
• Pneumonia Care PN-3a Blood culture - Percent of pneumonia patients, age 18 years or older, transferred or admitted to the ICU within 24 hours of hospital arrival who had blood cultures performed within 24 hours prior to or 24 hours after arrival at the hospital.
  
• Infection SCIP Inf-1 Prophylactic antibiotic received within 1 hour prior to surgical incision - Surgical patients with prophylactic antibiotics initiated within 1 hour prior to surgical incision. Patients who received vancomycin or a fluoroquinolone for prophylactic antibiotics should have the antibiotics initiated within 2 hours prior to surgical incision. Due to the longer infusion time required for vancomycin or a fluoroquinolone, it is acceptable to start these antibiotics within 2 hours prior to incision time.
  
• Infection SCIP Inf-3 Prophylactic antibiotics discontinued within 24 hours after surgery end time - Surgical patients whose prophylactic antibiotics were discontinued within 24 hours after Anesthesia End Time.

Data Submission

Medicare EPs and eligible hospitals would be required to report the required clinical quality measures information electronically using certified EHR technology via one of three methods.

1. The primary method would require the EP or eligible hospital to log into a CMS-designated portal. Once the EP or eligible hospital has logged into the portal, they would be required to submit, through an upload process, data payload based on specified structures, such as Clinical Data Architecture (CDA), and accompanying templates produced as output from their certified EHR technology.
2. As an alternative to this data submission method, Medicare EPs and eligible hospitals may submit the required clinical quality measures data using certified EHR technology through Health Information Exchange (HIE)/Health Information Organization (HIO). This alternative data submission method would be dependent on the Secretary's ability to collect data through a HIE/HIO network and would require the EP or eligible hospital who chooses to submit data via an HIE/HIO network to be a participating member of the HIE/HIO network. Medicare EPs and eligible hospitals would be required to submit their data payload based on specified structures or profiles, such as Clinical Data Architecture (CDA), and accompanying templates. The EP's or eligible hospital's data payload should be an output from their respective certified EHR products, in the form and manner specified from their HIE/HIO adopted architecture into the CMS HIE/HIO adopted architecture.
3. As another potential alternative, submission be accepted through registries dependent upon the development of the necessary capacity and infrastructure to do so using certified EHRs.

Methods for Demonstration of the Stage 1 Criteria of Meaningful Use
For CY 2011 and FY 2011, EPs and eligible hospitals demonstrate that they satisfy each of the proposed meaningful use objectives through attestation. For payment years beginning in CY and FY 2012 and subsequent years, EPs and eligible hospitals demonstrate that they satisfy each of the proposed quality measures through electronic reporting and the remainder through attestation.

Incentive payments for EPs
Incentives will be made at the EP level, not at the group practice level. EPs that change practices may continue their incentive payments at their new practice. EP's that no longer qualify for Medicaid incentives due to such a change, may elect a one-time change to the Medicare program.

Administrative data to be collected

• Name, NPI, business address, and business phone of each EP or eligible hospital.
• Taxpayer Identification Number (TIN) to which the EP or eligible hospital wants the incentive payment made. For Medicaid EPs this must be consistent with assignment rules
• For EPs, whether they elect to participate in the Medicare EHR incentive programs or the Medicaid EHR incentive program.
• For eligible hospitals, their CCN.

Hospital

Hospital-based Professionals are not eligible for the Medicare incentive payments. Most are also not eligible for Medicaid, unless they practice predominantly in an FQHC or RHC. A Professional is considered hospital-based if substantially all (90%) of the professional services are in the inpatient or outpatient hospital settings, based on the place of service (POS) codes on physician claims.

Stage 1 meaningful use criteria for eligible hospitals apply to the hospital's inpatient setting only.

e-Prescribing interaction
If a Medicare FFS or MA EP receives an incentive payment from the Medicare EHR incentive program, the EP (or group practice) is not eligible to also receive the incentive payment under the E-prescribing Incentive Program created by MIPPA. EPs receiving a Medicaid EHR incentive payment would remain eligible for the Medicare MIPAA E-Prescribing Incentive Program payment.

Eligible Professional

An Eligible Professional is one of five types of professionals, each of which must be legally authorized to practice their profession under state law: a doctor of medicine or osteopathy, a doctor of dental surgery or dental medicine, a doctor of podiatric medicine, a doctor of optometry, or a chiropractor.

Medicare Compensation for EP's

For EPs working with more than one practice, the EP selects one tax identification number to receive the applicable EHR incentive payment.


EP Services in Geographic Health Professional Shortage Area (HPSA)

EPs that provide service in designated HPSA's are entitled to an increased incentive payment limit of 10 percent per year. EP's that provider more than 50% of their service in an HPSA (for claims submitted within 60 days of calendar year-end) and otherwise meet the meaningful use requirements are entitled to the increased incentive payment.

EP Payment Adjustments

These adjustments (penalties) start in 2015 for EPs who are not Meaningful Users of Certified EHR Technology. Beginning in 2015, if an EP is not a meaningful EHR user for any EHR reporting period for the year, then the Medicare physician fee schedule is adjusted by the applicable percent': “(I) for 2015, 99 percent (or, in the case of an EP who was subject to the application of the payment adjustment if the EP is not a successful electronic prescriber under section 1848(a)(5) for 2014, 98 percent);” “(II) for 2016, 98 percent; and (III) for 2017 and each subsequent year, 97 percent.” In addition, if for 2018 and subsequent years the Secretary finds that the proportion of EPs who are meaningful EHR users is less than 75 percent, the applicable percent shall be decreased by 1 percentage point from the applicable percent in the preceding year, but in no case shall the applicable percent be less than 95 percent. There is a significant hardship exception which cannot exceed 5 additional years.

Hospital Payments

The hospital payment methodology starts with an initial amount calculated as a base amount ($2 million) and adds a discharge related amount based on the number of discharges for the period ($200 for discharges from 1,150 up to 23,000 discharges). The initial amount is then multiplied by the Medicare Share and an applicable transition factor to determine the incentive payment for an incentive payment year.

Adjustments to the market basket update to the IPPS payment rate will be made for hospitals that are not meaningful users by 2015.

Qualifying Medicare Advantage Eligible Professional
A qualifying MA organization may receive an incentive payment for EP's that are employed by the qualifying MA organization; or are employed by, or be a partner of, an entity that through contract with the qualifying MA organization furnishes at least 80 percent of the entity's Medicare patient care services to enrollees of the qualifying MA organization. Further, the EP must furnish at least 80 percent of his or her professional services covered under Medicare to enrollees of the qualifying MA organization and must furnish, on average, at least 20 hours per week of patient care services during the EHR reporting period.

The payment rules for MA organizations are beyond the scope of this article.

Medicaid Program Participation A “Medicaid EP” is a Medicaid professionals including : physicians, dentists, certified nurse-midwives, nurse practitioners, and physician assistants practicing in an FQHC or RHC that is so led by a physician assistant. Additionally, to qualify for incentives, most Medicaid EPs cannot be hospital-based, unless practicing in an FQHC or RHC. Medicaid EPs must also meet the patient volume thresholds or practice predominantly in an FQHC or RHC. Medicaid EPs must have at least 30 percent patient volume attributable to those who are receiving Medicaid (20 percent for pediatricians).

Acute care hospitals and separately certified children's hospitals are eligible under the Medicaid program if they have at least 10% of Medicaid patient volume, but not long-term care facilities (where the average length of patient stay is greater than 25 days).

Calculation of the 30 percent of all patient encounters is attributable to needy individuals over any continuous 90-day period within the most recent calendar year prior to reporting. Needy individuals include: (1) they are receiving medical assistance from Medicaid or the Children's Health Insurance Program (CHIP); (2) they are furnished uncompensated care by the provider; or (3) they are furnished services at either no cost or reduced cost based on a sliding scale determined by the individual's ability to pay.

Medicaid EPs may voluntarily assign payments to entities promoting EHR technology so long as the assignee does not retain more than 5 percent of the Medicaid incentive payments for costs unrelated to certified EHR technology. Health information exchanges are one example of such entities and have the potential to transform the healthcare system by facilitating timely, accurate, and portable health information on each patient at the point of service. HIEs provide the capability to move clinical information electronically between disparate health care information systems while maintaining the meaning of the information being exchanged. HIEs also provide the infrastructure for secondary use of clinical data for purposes such as public health, clinical, biomedical, and consumer health informatics research as well as institution and provider quality assessment and improvement, where permissible under HIPAA and other requirements included in the HITECH Act. In addition, use of health information exchange models can reduce the need for costly point-to-point interfaces between different EHR tools, as used in laboratories and pharmacies, thus providing a more scalable model of interoperable health information exchange. HIEs promote adoption of certified EHR technology by providing the infrastructure for providers' EHRs to reach outside of their clinical practice sites and connect with other points of care. Providers report that having a more complete picture of their patients' healthcare data from other providers and care settings is one of the primary appeals to using EHRs. Without health information exchange, electronic health records are simply digitized filing cabinets and will not achieve their quality of care or cost containment potential. Furthermore, given the proposed definition of meaningful use, HIEs can significantly help Medicaid providers adopt and use EHR in such a way that the goals of the incentive program are met. The inclusion in HITECH of HIE grants to be awarded to States or State-designated Entities by ONC are an additional indication of the symbiotic relationship between health information exchanges and optimal use of EHRs.

Unlike the Medicare incentive programs, the Medicaid program allows eligible providers to receive an incentive payment even before they have begun to meaningfully use certified EHR technology. These providers may receive a first year of payment if they are engaged in efforts to “adopt, implement, or upgrade” to certified EHR technology.

“Implement” means that the provider has installed certified EHR technology and has started using the certified EHR technology in his or her clinical practice. Implementation activities would include staff training in the certified EHR technology, the data entry of their patients' demographic and administrative data into the EHR, or establishing data exchange agreements and relationships between the provider's certified EHR technology and other providers, such as laboratories, pharmacies, or HIEs.

“Upgrade” means the expansion of the functionality of the certified EHR technology, such as the addition of clinical decision support, eprescribing functionality, CPOE or other enhancements that facilitate the meaningful use of certified EHR technology.

A Medicaid EP would not need to demonstrate that it has adopted, implemented, or upgraded certified EHR technology in year one of the program, if they can already demonstrate meaningful use of such technology.

Estimates of Meaningful Use Adoption by EPs - Medicare

Estimates of Meaningful Use Adoption by EPs - Medicaid